Management of Neurogenic Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients

Current Urology Reports

Volumn 16, Issue 7, 2015, Pages

  Sadiq, Areeba ^a   Brucker, Benjamin M ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder dysfunction in multiple sclerosis; Management of neurogenic lower urinary tract dysfunction; Multiple sclerosis; Neurogenic bladder; Neurogenic detrusor overactivity; Treatment of bladder dysfunction

Indexed keywords

BOTULINUM TOXIN A; CANNABINOID; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; FESOTERODINE; MIRABEGRON; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; BOTULINUM TOXIN;

ABDOMINAL VIBRATION; ACTIONABLE BLADDER SYMPTOM AND SCREENING TOOL; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONSERVATIVE TREATMENT; CREDE MANEUVER; DETRUSOR DYSSYNERGIA; EXPANDED DISABILITY STATUS SCALE; HEADACHE; HUMAN; HYPERNATREMIA; HYPONATREMIA; ICIQ (INCONTINENCE); INDWELLING CATHETER; INTERMITTENT CATHETERIZATION; KINGS HEALTH QUESTIONNAIRE; LOWER URINARY TRACT SYMPTOM; MULTIPLE SCLEROSIS; NERVE STIMULATION; NERVE STIMULATOR; NEUROGENIC BLADDER SYMPTOM SCORE; NEUROGENIC LOWER URINARY TRACT SYMPTOM; NEUROLOGIC DISEASE; NEUROMODULATION; NOCTURIA; OVERACTIVE BLADDER; OVERACTIVE BLADDER QUESTIONNAIRE; PELVIC FLOOR MUSCLE TRAINING; PERCUTANEOUS TIBIAL NERVE STIMULATION; POLYURIA; QUALITY OF LIFE; REVIEW; SACRAL NERVE STIMULATION; SCREENING TEST; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URINARY DIVERSION; URINARY TRACT DISEASE ASSESSMENT; URINARY TRACT INFECTION; URODYNAMICS; VESICOURETERAL REFLUX; XEROSTOMIA; ANIMAL; COMPLICATION; KINESIOTHERAPY; TREATMENT OUTCOME; UROLOGIC DISEASES; VIBRATION;

ANIMALS; BOTULINUM TOXINS; EXERCISE THERAPY; HUMANS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME; UROLOGIC DISEASES; VIBRATION;

EID: 84930210912     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0519-5     Document Type: Review

References (58)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31.
2. Rubin SM. Management of multiple sclerosis: an overview. Dis Mon. 2013;59(7):253–60.
3. World Health Organization. Atlas: Multiple sclerosis resources in the world. 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf
4. Khan F, Pallant JF, Shea TL, et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil. 2009;31:1567–76.
5. Yonnet GJ, Fjeldstad AS, Carlson NG, Rose JW. Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Care. 2013;15(2):66–72.
6. Drake M, Apostolidis A, Emmanuel A, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence (5th Ed). ICUD-EAU; 2013.p. 827–1000.
7. Haab F. Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn. 2014;33:S2–5.
8. Kim JH. Management of urinary and bowel dysfunction in multiple sclerosis. In: Giesser BS, editor. Primer on multiple sclerosis. New York: Oxford University Press; 2011. p. 197–206.
9. Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology. 2013;41(3–4):146–55. This article provides a thorough review to best estimate the prevalence of urinary incontinence caused by various neurological conditions including multiple sclerosis, spinal cord injury, Parkinson’s disease, and stroke.
10. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. International Francophone Neuro-Urological Expert Study Group (GENULF): the neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13:915–28.
11. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161:743–57.
12. Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010;183(4):1432–7. This large analysis of 9,702 MS patient responses from the North American Research Committee on Multiple Sclerosis survey showed that despite a high prevalence of overactive bladder symptoms in this population, only 43% were seen by a urologist, only 51% had been treated with anticholinergics, and less than 10% were given newer treatments.
13. Khalaf KM, Coyne KS, Globe DR, Armstrong EP, Malone DC, and Burks J. Lower Urinary Tract Symptom Prevalence and Management Among Patients with Multiple Sclerosis. Int J MS Care 2014;In-Press. doi:10.7224/1537-2073.2013-040. This large study of 1,052 MS patients survey responses clearly defines the prevalence of specific LUTS and its relationship to seeking a health care provider. Urgency, intermittent stream, and urgency UI were all predictors of seeking treatment. This study points out the high prevalence of LUTS, yet a gap in urologic evaluation of these patients.
14. Burks J, Chancellor M, Bates B, Denys P, MacDiarmid S, Nitti V, et al. Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients. Int J MS Care Winter. 2013;15(4):182–92. The Actionable Bladder Symptom and Screening Tool (ABSST) was developed as an easy way health care professionals to quickly identify patients who may need further evaluation for bladder symptoms covering multiple dimensions relevant to MS patients and leading to a referral when appropriate. The 17-item form (or 8-item short form) contains questions in three domains including Bladder Symptoms, Coping Strategies, and Impact of Bladder Symptoms as well as a question that asks the patient whether they would like help for their bladder symptoms.
15. Bates D, Burks J, Globe D, Signori M, Hudgens S, Denys P, et al. Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurol. 2013;13:78.
16. Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014;192(2):452–7. The Neurogenic Bladder Symptom Score (NBSS) is the first patient reported outcome measure designed to assess objective signs and symptoms related to neurogenic bladder dysfunction from spinal cord injury, spina bifida, and MS in order to objectively discriminate among patients with different levels of bladder symptoms, rather than simply from the general population. The 22-item tool cover three major domains—Incontinence, Storage and Voiding Symptoms, and Urinary Complications.
17. Welk B, Morrow S, Madarasz W, Potter P, Sequeira K. The conceptualization and development of a patient-reported neurogenic bladder symptom score. Res Rep Urol. 2013;5:129–37.
18. Aponte M, Sadiq A, Utomo P, Herbert J, Rosenblum N, Nitti V, et al. Urologic barriers to care in patients with multiple sclerosis. Neurourol Urodyn. 2014;33(2):206. A prospective observational study of 100 MS patients identifying the most common barriers to seeking urologic treatment including physician not referring (18%), physician not asking (15%), lack of knowledge of treatment options (12.5%), and embarrassment (10%). Those with an Actionable Bladder Symptoms and Screening Tool score ≥3 were more likely to cite cost, insurance, transportation, or accessibility as barriers.
19. Fowler C, Panicker J, Drake M, Harris C, Harrison S, Kirby M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:470–7.
20. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205–9.
21. McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis. A randomized pilot study. Neurourol Urodyn. 2006;25(4):337–48.
22. Rovner R, Wyman J, Lackner T, Guay D. Urinary incontinence. In: Dipiro J, Talbert R, Yee G, Matzke Wells B, Posey L, editors. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill Medical Publishing Division; 2002. p. 1543–56.
23. Andersson KE. Current and future drugs for treatment of MS-associated bladder dysfunction. Ann Phys Rehab Med. 2014;57(5):321–8.
24. Lamin E, Smith A. Urologic agents for treatment of bladder dysfunction in neurologic disease. Curr Treat Options Neurol. 2014;16:280.
25. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62:816–30.
26. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009;21(1):CD004193.
27. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753.
28. Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(1):1–5.
29. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26:752–6.
30. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta 3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian Phase 3 Trial. Eur Urol. 2013;63:283–95. This phase 3 trial of mirabegron in patients with idiopathic overactive bladder demonstrated a significant decrease in frequency of micturition and lower number of incontinence episodes when compared to placebo. Its efficacy and good tolerability may represent a new class of drugs to aid MS patients due to its favorable side effect profile.
31. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.
32. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int Urogynecol J. 2006;17:636–41.
33. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10(4):425–33.
34. Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81:215–8.
35. Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72:13–24.
36. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. This seminal trial of 275 patients demonstrated the efficacy of OnabotulinumtoxinA 200U over placebo, by significantly reducing UI episodes in those patients with NDO refractory to anticholinergic therapy.
37. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30(9):819–33. This seminal trial of 416 patients further demonstrated the efficacy of OnabotulinumtoxinA 200U over placebo by also significantly lowering UI episodes in those patients with NDO refractory to anticholinergic therapy. Furthermore, these results were true when looking specifically at the MS subset population in this study.
38. Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:1109–15. With combined the data from both OnabotulinumtoxinA trials (Cruz et al. and Ginsberg et al.), this study demonstrates that significantly more patients with low baseline detrusor contractility did not experience involuntary detrusor contractions at week 6 after being treated with 200 or 300 U onabotulinumtoxinA when compared to placebo (60% vs. 13%).
39. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30(9):819–33.
40. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.
41. Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37(5):642–8.
42. Staskin D, Peters K, MacDiarmid S, Shore N, de Groat W. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012;13(5):327–34.
43. Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014;191(3):697–702. This prospective non-placebo controlled trial of 83 MS patients with LUTS refractory to medical therapy demonstrated that 89% had a 50% or greater improvement in symptoms after initial treatment of PTNS that lasted for 2 years with a typical maintenance regimen. There were significant decreases in daytime frequency, nocturia, and improvements on urodynamic parameters. This represents a minimally invasive approach for symptomatic relief that will require more work to better understand its role and the ideal candidate.
44. Gobbi C, Digesu GA, Khullar V. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicenter, prospective, open label trial. Mult Scler. 2011;17:1514.
45. Lemack GE. Percutaneous tibial nerve stimulation for refractory lower urinary tract symptoms in patients with neurogenic bladder conditions. J Urol. 2014;191(3):582–3.
46. Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30:123–8.
47. Pannek J, Blok B, Castro-Diaz D, Del Popolo G, Kramer G, Radziszewski P, Reitz A, Stöhrer M, Wyndaele J. Guidelines Neurogenic Lower Urinary Tract Dysfunction. European Association of Urology. 2013. http://www.uroweb.org/gls/pdf/20_Neurogenic%20LUTD_LR.pdf
48. Newman D, Willson M. Review of intermittent catheterization and current best practices. Urol Nurs. 2011;31(1):10–2.
49. Mahajan S, Frasure H, Marrie R. The prevalence of urinary catheterization in women and men with multiple sclerosis. J Spinal Cord Med. 2013;36(6):632–7.
50. Chang SM, Hou CL, Dong DQ, Zhang H. Urologic status of 74 spinal cord injury patients from the 1976 Tangshan earthquake, and managed for over 20 years using the Crede maneuver. Spinal Cord. 2000;38(9):552–4.
51. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid in bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(1):42–7.
52. Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004;1:CD002802.
53. Winters J, Dmochowski R, Goldman H, Herndon C, Kobashi K, Kraus S, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188:2464–72. This is a comprehensive guideline for the use of urodynamics studies when evaluating patients with varied LUTS.
54. Weidemann A, Kaeder M, Greulick W, Lax H, Priebel J, Kirschner-Hermanns R, et al. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? An analysis of 100 prospective cases. World J Urol. 2013;31(1):229–33.
55. Ciano S, Mutchnik S, Rivera V, Boone T. Urodynamic pattern changes in multiple sclerosis. Urology. 2001;57(2):239–45.
56. Dillon B, Lemack G. Urodynamics in the evaluation of the patient with multiple sclerosis: when are they helpful and how do we use them? Urol Clin N Am. 2014;41(3):439–44. This paper recommends symptomatic management and non-invasive studies when evaluating MS patients because the majority will have urodynamic abnormalities. Those with elevated PVR (>150mL), 2 or more failed trials of medical therapy, obstructive symptoms, or hydronephrosis should receive an initial UDS, although other situations are at the discretion of the physician.
57. Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. J Urol. 2003;169(1):195–8.
58. Stein R, Schroder A, Thuroff J. Bladder augmentation and urinary diversion in patients with neurogenic bladder: surgical considerations. J Pediatr Urol. 2012;8(2):153.